Dr. Tseng serves as Medical Director of Ocular Surface Center, providing the state-of-art Clinical Services to patients suffering from a variety of ocular surface and tear disorders.

Dr. Tseng serves as Research Director of Ocular Surface Foundation, educating and training research fellows who are to be specialized in ocular surface biology, health, and diseases.

Dr. Tseng serves as Director of Research & Development of TissueTech, Inc., Medical Director and Consultant of Bio-Tissue, Inc., and Director of Research & Development of Bio-Lipid, Inc., supervising a variety of Research Programs directed to study the pathogenesis of ocular surface and tear diseases, and develop new tools and products for improving the diagnosis and treatment of these diseases.

Office Location: Ocular Surface Center, P.A.
7235 NW 19th St | Map This
Suite C
Miami, FL 33126, USA
E-mails: stseng@ocularsurface.com
Office Phone: (305) 274-1299
Cellular Phone: (305) 803-6925
Office Fax: (305) 274-1297


Dr. Tseng has obtained the FDA approval (under IND# 10313) and NIH grant support to conduct Phase I clinical trial to determine the safety and efficacy of Transplantation of Ex Vivo Expanded Limbal Epithelial Stem Cells for Treating Limbal Stem Cell Deficiency.
Dr. Tseng received Senior Achievement Award from American Academy of Ophthalmology during the annual meeting at New Orleans, LA in 2004.
Dr. Tseng gave Kersley Lecture  at the annual meeting of Medical Contact Lens and Ocular Surface Association (MCLOSA) in London, UK, on Nov 19, 2004 and Oliver H. Dabezies Jr. M.D. Lecture at the annual meeting of Contact Lens Association of Ophthalmology (CLAO) in San Diego, CA, on Jan 22, 2005.
Dr. Tseng served as a member of the expert panel for Interagency Coordinating Committee on Validation of Alternative Methods (ICCVAM) sponsored by NIH, August 2004 - January 2005.
Dr. Tseng has summarized in a recent review explaining how amniotic membrane works in ocular surface reconstruction.
Dr. Tseng and his colleagues have discovered several new applications of amniotic membrane transplantation.  Amniotic membrane can help both the donor and recipient eyes receiving conjunctival limbal autograft and restore deep fornix during symblepharon lysis (especially in conjunction with intraoperative application of mitomycin C).
Dr. Tseng and his colleagues have discovered that conjunctivochalasis-induced dry eye an be differentiated from aqueous tear deficiency-induced dry eye, and that lipid tear deficiency due to meibomian gland dysfunction is the dominant cause for persistent dry eye following LASIK using kinetic analysis of tear interference images.
Clinical Services
Practice exclusively limited to Ocular Surface and Tear Diseases. More... 
Research Programs
Committed to the exploration and resolution of Ocular Surface Disorders and treatments. More...
Fellowship Programs
Providing innovative, state of the art training in the subspecialty of Ocular Surface and Tear Disorders. More...